LFW

Kevin J. Tracey and Haichao Wang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/719,150

Group Art Unit: 3754

Filed:

Confirmation No.:

November 21, 2003

Examiner:

Not vet assigned

Title:

3380

Antagonists of HMG1 for Treating Inflammatory Conditions

CERTIFICATE OF MAILING OR TRANSMISSION							
I hereby certify that this correspondence is being deposited with the United States							
Postal Service with sufficient postage as First Class Mail in an envelope addressed							
to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is							
being facsimile transmitted to the United States Patent and Trademark Office on:							
6-9-04 Jane Yharean							
Date // Signature //							
TAIR UKCALI)							
UTINE THE STREET							
Typed or printed name of person signing certificate							

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or []

(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or

> a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with: []

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statem	ent Und	der 37 C	ZFR 1.97(e)						
[]	any co	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or							
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.								
Statem	ent Un	der 37 C	CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000						
[]	was no	unicatio t receiv	nformation contained in the Information Disclosure Statement was cited in a n from a foreign patent office in a counterpart application and this communication edd by any individual designated in § 1.56(c) more than thirty days prior to the formation Disclosure Statement.						
[X]	Enclos	ed here	with is form PTO-1449:						
	[X] A copy of the cited reference (AV5) is enclosed.								
		[]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.						
[] Copies of the cited references are enclosed except those er Application No. [], to which priority under 35 U.S.C application contains copies of the cited references.]									
	[]	The lis	ted references were cited in the enclosed International Search Report in a rpart foreign application.						
	[] The "concise explanation" requirement (non-English references) for referen under 37 CFR 1.98(a)(3) is satisfied by:								
		[]	the explanation provided on the attached sheet.						
		[]	the explanation provided in the Specification.						
		[]	submission of the enclosed International Search Report.						
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.						
		[]	the enclosed English language abstract.						

[]	Applie	cant requests that the following r	non-published pending applic	cations be considered:					
Examiner's	:								
	_	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []					
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []					
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []					
		Examiner	Date	-					
	[]	A copy of each above-cited app	plication, including the curre	nt claims, is enclosed.					
	[]	A copy of each above-cited app those entered in prior applicati 35 U.S.C. 120 is claimed.		nt claims, is enclosed, except], to which priority under					
The E refere	xamine nces we	r is requested to return a copy of tre considered with the next office	the above list of pending ap	plications indicating which					
It is re	questec	I that the information disclosed I	nerein be made of record in the	his application.					
Metho	od of pa	yment:							
[]	A che	ck for the fee noted above is encupanying Reply. A copy of this	losed, or the fee has been inc Statement is enclosed.	cluded in the check with the					
[]	Please	charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is ed.							
[X]	Please	charge any deficiency in fees a	nd credit any overpayment to	Deposit Account 08-0380.					
		1	Respectfully submitted,						
		1	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.					
		1	David E. Brook Registration No.: 22,592 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	<u> </u>					

Concord, MA 01742-9133 Dated: 6/9/64

						Sheet 1 of 1							
PTO-1449		•	ATTORNEY DOCKET NO. APPLICATION NO. 3268.1000-012 10/719,150										
SU	PPLEM C	MENTAL INFORMATION DISCLOSUREE	FIRST NAMED INVENTOR	FILING DATE November 21, 2003									
		June 8, 2004 JUN 1 1 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 3380	GROUP 3754								
	THANKAR!												
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	AV5	Uesugi, H., et al., "Prevalence and Char- Group Non-Histone Chromosomal Prote Rheumatol., 25(4):703-709 (1998).	acterization of Novel pANCA, A pins HMG1 and HMG2, in Syste	Antibo	dies to the Hig heumatic Dise	gh Mobility eases," J.							
	·												
						40.40							

EXAMINER DATE CONSIDERED